Myeloproliferative Disorders Research Consoritum Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Chicago IL United States (2006)

Organization Overview

First Clinical Trial
2007
NCT00572897
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Myeloproliferative Disorders-Research Consortium

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 2)

Polycythemia (Phase 3)

Polycythemia Vera (Phase 3)

Primary Myelofibrosis (Phase 2)

Thrombocythemia, Essential (Phase 3)

Thrombocytosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 11